CN102076215A - 5-氟胞嘧啶制剂及其用途 - Google Patents

5-氟胞嘧啶制剂及其用途 Download PDF

Info

Publication number
CN102076215A
CN102076215A CN200980125558XA CN200980125558A CN102076215A CN 102076215 A CN102076215 A CN 102076215A CN 200980125558X A CN200980125558X A CN 200980125558XA CN 200980125558 A CN200980125558 A CN 200980125558A CN 102076215 A CN102076215 A CN 102076215A
Authority
CN
China
Prior art keywords
hours
pharmaceutical composition
delivery formulations
polymer
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200980125558XA
Other languages
English (en)
Chinese (zh)
Inventor
哈利·E·格鲁贝尔
道格拉斯·乔利
K·奥尔姆斯蒂德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forte Biosciences Inc
Original Assignee
Tocagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tocagen Inc filed Critical Tocagen Inc
Priority to CN201710036517.XA priority Critical patent/CN107029220A/zh
Publication of CN102076215A publication Critical patent/CN102076215A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04001—Cytosine deaminase (3.5.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN200980125558XA 2008-06-30 2009-06-30 5-氟胞嘧啶制剂及其用途 Pending CN102076215A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710036517.XA CN107029220A (zh) 2008-06-30 2009-06-30 5‑氟胞嘧啶制剂及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7714208P 2008-06-30 2008-06-30
US61/077,142 2008-06-30
PCT/US2009/049322 WO2010002937A1 (en) 2008-06-30 2009-06-30 Formulations of 5-fluorocytosine and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710036517.XA Division CN107029220A (zh) 2008-06-30 2009-06-30 5‑氟胞嘧啶制剂及其用途

Publications (1)

Publication Number Publication Date
CN102076215A true CN102076215A (zh) 2011-05-25

Family

ID=41466310

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200980125558XA Pending CN102076215A (zh) 2008-06-30 2009-06-30 5-氟胞嘧啶制剂及其用途
CN201710036517.XA Pending CN107029220A (zh) 2008-06-30 2009-06-30 5‑氟胞嘧啶制剂及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710036517.XA Pending CN107029220A (zh) 2008-06-30 2009-06-30 5‑氟胞嘧啶制剂及其用途

Country Status (11)

Country Link
US (4) US9320738B2 (enExample)
EP (1) EP2306823A4 (enExample)
JP (3) JP6092514B2 (enExample)
KR (2) KR101950635B1 (enExample)
CN (2) CN102076215A (enExample)
AU (1) AU2009267052B2 (enExample)
BR (1) BRPI0915284B1 (enExample)
CA (1) CA2724740C (enExample)
IL (3) IL209385A (enExample)
MX (2) MX337213B (enExample)
WO (1) WO2010002937A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579450A (zh) * 2012-02-10 2012-07-18 上海市嘉定区南翔医院 5-氟尿嘧啶在制备局限性慢性湿疹治疗药物上的应用
CN111937887A (zh) * 2020-07-15 2020-11-17 南京师范大学 5-氟-2’-脱氧尿苷在抑制和/或防治螺旋藻规模化生产中褶皱臂尾轮虫的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018240A1 (en) 1998-10-01 2000-04-06 University Of Southern California Gene delivery system and methods of use
US9320738B2 (en) * 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102227503B (zh) 2008-09-26 2015-10-21 托卡根公司 重组载体
JP5923037B2 (ja) 2009-06-17 2016-05-24 トカジェン インコーポレーテッド 複製可能レトロウイルスベクターの産生細胞
CA2779711C (en) * 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
WO2012058673A2 (en) 2010-10-31 2012-05-03 Tocagen Inc. Enhanced cancer treatment and monitoring using recombinant vectors
EP2670368A4 (en) * 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
WO2013004658A1 (en) * 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
EP2668945A1 (de) 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen
WO2014066700A1 (en) 2012-10-25 2014-05-01 Tocagen Inc. Retroviral vector with mini-promoter cassette
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
US11279949B2 (en) 2015-09-04 2022-03-22 Denovo Biopharma Llc Recombinant vectors comprising 2A peptide
WO2018169900A1 (en) * 2017-03-14 2018-09-20 Memorial Sloan Kettering Cancer Center Labeling, isolation, & analysis of rna from rare cell populations
US20190380965A1 (en) * 2018-06-15 2019-12-19 Hemant N. Joshi Quick Water-Dispersible Pharmaceutical Compositions of Flucytosine
EP3955943A4 (en) * 2019-02-22 2023-10-25 Candel Therapeutics, Inc. Gmci and ddri combination therapy for treating cancer
CN115516833B (zh) 2020-03-18 2025-01-03 马维尔以色列(M.I.S.L.)有限公司 网络设备中的分组缓冲溢出

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105486C (en) 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
FI980901A7 (fi) 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
WO2000018240A1 (en) 1998-10-01 2000-04-06 University Of Southern California Gene delivery system and methods of use
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
WO2001004266A1 (en) 1999-07-08 2001-01-18 The Regents Of The Universty Of California A lung cancer associated retrovirus, gene delivery vector and methods of use thereof
JP4021627B2 (ja) * 2000-03-22 2007-12-12 株式会社東芝 遺伝子検出用担体、及びインターフェロン療法の有効性を検出するためのその使用
IL153497A0 (en) 2000-06-23 2003-07-06 Teva Pharma Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CN1244321C (zh) * 2003-06-26 2006-03-08 李勇 用于胃癌治疗的5－氟尿嘧啶胃内漂浮滞留双层缓释片
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
US8715727B2 (en) * 2004-07-02 2014-05-06 Shionogi Inc. Tablet for pulsed delivery
FR2874325B1 (fr) 2004-08-19 2006-10-20 Sanofi Synthelabo Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
WO2006127980A2 (en) 2005-05-25 2006-11-30 The Regents Of The University Of California Optimized core promoters and uses therefor
WO2007069358A1 (ja) * 2005-12-14 2007-06-21 Kissei Pharmaceutical Co., Ltd. 新規胃内滞留製剤
CN101085355B (zh) * 2007-06-20 2012-01-25 山东大学 5-氟胞嘧啶/类水滑石纳米杂化物及其制备方法
US20090068287A1 (en) 2007-09-12 2009-03-12 Susan Welsh Novel topical formulations of flucytosine and uses thereof
US9314524B2 (en) 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
US9320738B2 (en) * 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
CN102227503B (zh) 2008-09-26 2015-10-21 托卡根公司 重组载体
US8829173B2 (en) 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
US9187762B2 (en) 2010-08-13 2015-11-17 Pioneer Hi-Bred International, Inc. Compositions and methods comprising sequences having hydroxyphenylpyruvate dioxygenase (HPPD) activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667060B1 (en) * 1999-03-31 2003-12-23 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A.VERMES ET AL: "flucytosine:a review of its pharmacology,clinical indications pharmacokinetics,toxicity and drug interactions", 《JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579450A (zh) * 2012-02-10 2012-07-18 上海市嘉定区南翔医院 5-氟尿嘧啶在制备局限性慢性湿疹治疗药物上的应用
CN102579450B (zh) * 2012-02-10 2013-07-24 上海市嘉定区南翔医院 5-氟尿嘧啶在制备局限性慢性湿疹治疗药物上的应用
CN111937887A (zh) * 2020-07-15 2020-11-17 南京师范大学 5-氟-2’-脱氧尿苷在抑制和/或防治螺旋藻规模化生产中褶皱臂尾轮虫的应用

Also Published As

Publication number Publication date
CA2724740C (en) 2017-02-21
CA2724740A1 (en) 2010-01-07
BRPI0915284A2 (pt) 2015-08-04
JP2015063533A (ja) 2015-04-09
IL255813A (en) 2018-01-31
CN107029220A (zh) 2017-08-11
US9889133B2 (en) 2018-02-13
KR20110039544A (ko) 2011-04-19
EP2306823A4 (en) 2012-09-26
JP6092514B2 (ja) 2017-03-08
KR101813721B1 (ko) 2017-12-29
AU2009267052B2 (en) 2013-07-11
JP2011526918A (ja) 2011-10-20
US20200281929A1 (en) 2020-09-10
JP6170896B2 (ja) 2017-07-26
US11191764B2 (en) 2021-12-07
US10449194B2 (en) 2019-10-22
JP2017214398A (ja) 2017-12-07
BRPI0915284B1 (pt) 2020-01-14
IL209385A (en) 2016-10-31
AU2009267052A1 (en) 2010-01-07
IL246473B (en) 2018-06-28
US20160235751A1 (en) 2016-08-18
WO2010002937A1 (en) 2010-01-07
MX2010014256A (es) 2011-07-01
IL209385A0 (en) 2011-01-31
MX337213B (es) 2016-02-17
US20110268720A1 (en) 2011-11-03
MX366570B (es) 2019-07-12
EP2306823A1 (en) 2011-04-13
KR101950635B1 (ko) 2019-05-20
US20190015414A1 (en) 2019-01-17
US9320738B2 (en) 2016-04-26
KR20180004279A (ko) 2018-01-10

Similar Documents

Publication Publication Date Title
US11191764B2 (en) Formulations of 5-fluorocytosine and uses thereof
ES2771458T3 (es) Formulación de combinación de dos compuestos antivirales
JP2010532746A (ja) 放出調節医薬組成物およびその製造方法
CN103118669B (zh) 口服药物治疗方法和组合物
US20190290629A1 (en) Niraparib sustained and controlled release pharmaceutical composition and use thereof
CN101360495B (zh) 对癌症病人给药mTOR抑制剂
JP7190425B2 (ja) 肝細胞癌の治療のための併用療法
CN101193638A (zh) 用于良性前列腺肥大疗法的组合
HK1239558A1 (en) Formulations of 5-fluorocytosine and uses thereof
HK1154755A (en) Formulations of 5-fluorocytosine and uses thereof
CN1969854A (zh) 一种雷替曲塞缓释制剂及其制备方法
AU2013205004B2 (en) Formulations of 5-fluorocytosine and Uses Thereof
WO2021234530A1 (en) Novel extended release composition of tofacitinib, its derivatives and salts
RU2839277C1 (ru) Новая композиция замедленного высвобождения тофацитиниба, его производных и солей
CN117642382A (zh) 苯基吡咯氨基胍盐和制剂
WO2008102235A1 (en) Controlled release formulations of alfuzosin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1154755

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110525

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1154755

Country of ref document: HK